HEALTHCARE
Global Antiviral Drugs Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global Antiviral Drugs Market, By Type (Branded, Generics), Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others), Age Group (Adult, Pediatric, Geriatric), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Target Indication (Human Immunodeficiency Virus Infection, Coronavirus Infection, Hepatitis, Herpes Simplex Virus Infection, Cytomegalovirus Infection, Influenza, Others), Drug Target (Virus Targets, Host Targets), Type of Therapy (Monotherapy, Combination Therapy), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
The global antiviral drugs market size is valued to be USD xx million in 2023 and is expected to reach USD xx million by 2032, and it is expected to register a CAGR of xx% over the forecast period 2024-2032.
Antiviral drugs are pharmaceuticals formulated to treat viral illnesses by preventing virus growth and reproduction. By focusing on particular phases of the viral life cycle, they stop the virus from proliferating and dispersing throughout the body. Antiviral medications are used to treat a variety of viral disorders, such as herpes, hepatitis, HIV, and influenza. The antiviral drug market includes the manufacturing, distribution, and selling of these pharmaceuticals. It includes the discovery of novel antiviral drugs through research and development, the marketing of antiviral medications, regulatory approvals, and clinical trials to evaluate the agents' safety and efficacy. Pharmaceutical companies, biotechnology companies, and healthcare providers are major players in this industry, and they are all striving to meet the increasing demand for efficient therapies against viral infections.
The respective global report analyses market trends, consumer behaviour and industry dynamics to guide towards entry into new markets with ease. Also, it assists in tailoring market specific and related products and services to meet the needs, preferences, and expectations of target audience by delving into their psychology. The report also specializes with comprehensive and extensive competitive analysis which offers useful insights into competitor strengths, weaknesses, opportunities, and threats. The respective report offers exclusive insights into the potential impact of disruptive developments and technologies that are expected to completely transform corporate operations. The context includes tailor-made research solutions to create a stronger footprint in their particular industries thereby offering dedicated customized solutions according to the client needs which helps in addressing unique business challenges with more simplified and efficient decision-making solutions.
Market Dynamics
DRIVERS
- Rise in viral infections like HIV, influenza, and COVID-19.
- Aging population driving higher incidence of viral diseases.
RESTRAINTS
- High cost of development and stringent regulatory processes.
- Emergence of drug-resistant viral strains.
OPPORTUNITIES
- Expansion in emerging markets.
- Development of novel antiviral therapies.
CHALLENGES
- Rapid mutation rates of viruses.
- Competition from generics.
SEGMENTATION
- Type
- Branded
- Generics
- Drug Class
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Neuraminidase Inhibitors
- Others
- Age Group
- Adult
- Pediatric
- Geriatric
- Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Target Indication
- Human Immunodeficiency Virus Infection
- Coronavirus Infection
- Hepatitis
- Herpes Simplex Virus Infection
- Cytomegalovirus Infection
- Influenza
- Others
- Drug Target
- Virus Targets
- Host Targets
- Type of Therapy
- Monotherapy
- Combination Therapy
The respective global report is completely customizable specific to regions (North America, Europe, Asia-Pacific, South America, Middle East and Africa), countries, and segments as per the client requirements.
REGIONAL SEGMENTATION
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- The Netherlands
- Belgium
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Malaysia
- Australia
- Thailand
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of South America
- Middle East and Africa
- Kingdom of Saudi Arabia
- South Africa
- U.A.E.
- Egypt
- Rest of Middle East and Africa
KEY MARKET PLAYERS
- Gilead Sciences
- AbbVie, Inc
- Merck & Co
- GlaxoSmithKline plc
- Aurobindo Pharma Limited
- ohnson & Johnson
- Sun Pharmaceutical Industries Ltd
- Cipla, Inc
- Mylan N V
- Bristol-Myers Squibb
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global Antiviral Drugs Market, by Type
- 3.2 Global Antiviral Drugs Market, by Drug Class
- 3.3 Global Antiviral Drugs Market, by Age Group
- 3.4 Global Antiviral Drugs Market, by Distribution Channel
- 3.5 Global Antiviral Drugs Market, by Target Indication
- 3.6 Global Antiviral Drugs Market, by Drug Target
- 3.7 Global Antiviral Drugs Market, by Type of Therapy
- 3.8 Global Antiviral Drugs Market, by Geography
- 3.9 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Increasing demand for broad-spectrum antiviral drugs.
- 5.1.2 Growing focus on combination therapies.
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Rise in viral infections like HIV, influenza, and COVID-17.
- 5.2.2 Aging population driving higher incidence of viral diseases
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 High cost of development and stringent regulatory processes.
- 5.3.2 Emergence of drug-resistant viral strains.
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Expansion in emerging markets.
- 5.4.2 Development of novel antiviral therapies.
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Rapid mutation rates of viruses.
- 5.5.2 Competition from generics.
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL ANTIVIRAL DRUGS MARKET, BY TYPE
- 6.1 Type Summary
- 6.2 Market Attractive Index
- 6.3 Global Antiviral Drugs Market, by Type (2019-2032)
- SECTION 7 - GLOBAL ANTIVIRAL DRUGS MARKET, BY DRUG CLASS
- 7.1 Drug Class Summary
- 7.2 Market Attractive Index
- 7.3 Global Antiviral Drugs Market, by Drug Class (2019-2032)
- SECTION 8 - GLOBAL ANTIVIRAL DRUGS MARKET, BY AGE GROUP
- 8.1 Age Group Summary
- 8.2 Market Attractive Index
- 8.3 Global Antiviral Drugs Market, by Age Group (2019-2032)
- SECTION 9 - GLOBAL ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 9.1 Distribution Channel Summary
- 9.2 Market Attractive Index
- 9.3 Global Antiviral Drugs Market, by Distribution Channel (2019-2032)
- SECTION 10 - GLOBAL ANTIVIRAL DRUGS MARKET, BY TARGET INDICATION
- 10.1 Target Indication Summary
- 10.2 Market Attractive Index
- 10.3 Global Antiviral Drugs Market, by Target Indication (2019-2032)
- SECTION 11 - GLOBAL ANTIVIRAL DRUGS MARKET, BY DRUG TARGET
- 11.1 Drug Target Summary
- 11.2 Market Attractive Index
- 11.3 Global Antiviral Drugs Market, by Drug Target (2019-2032)
- SECTION 12 - GLOBAL ANTIVIRAL DRUGS MARKET, BY TYPE OF THERAPY
- 12.1 Type of Therapy Summary
- 12.2 Market Attractive Index
- 12.3 Global Antiviral Drugs Market, by Type of Therapy (2019-2032)
- SECTION 13 - GLOBAL ANTIVIRAL DRUGS MARKET, BY GEOGRAPHY
- 13.1 Regional Summary
- 13.2 Market Attractive Index
- 13.3 Global Antiviral Drugs Market, by Geography (2019-2032)
- SECTION 14 - NORTH AMERICA ANTIVIRAL DRUGS MARKET
- 14.1 North America Summary
- 14.2 Market Attractive Index
- 14.3 North America Antiviral Drugs Market, by Type (2019-2032)
- 14.4 North America Antiviral Drugs Market, by Drug Class (2019-2032)
- 14.5 North America Antiviral Drugs Market, by Age Group (2019-2032)
- 14.6 North America Antiviral Drugs Market, by Distribution Channel (2019-2032)
- 14.7 North America Antiviral Drugs Market, by Target Indication (2019-2032)
- 14.8 North America Antiviral Drugs Market, by Drug Target (2019-2032)
- 14.9 North America Antiviral Drugs Market, by Type of Therapy (2019-2032)
- 14.10 North America Antiviral Drugs Market, by Country (2019-2032)
- 14.10.1 U.S.
- 14.10.2 Canada
- 14.10.3 Mexico
- 14.10.4 Rest of North America
- SECTION 15 - EUROPE ANTIVIRAL DRUGS MARKET
- 15.1 Europe Summary
- 15.2 Market Attractive Index
- 15.3 Europe Antiviral Drugs Market, by Type (2019-2032)
- 15.4 Europe Antiviral Drugs Market, by Drug Class (2019-2032)
- 15.5 Europe Antiviral Drugs Market, by Age Group (2019-2032)
- 15.6 Europe Antiviral Drugs Market, by Distribution Channel (2019-2032)
- 15.7 Europe Antiviral Drugs Market, by Target Indication (2019-2032)
- 15.8 Europe Antiviral Drugs Market, by Drug Target (2019-2032)
- 15.9 Europe Antiviral Drugs Market, by Type of Therapy (2019-2032)
- 15.10 Europe Antiviral Drugs Market, by Country (2019-2032)
- 15.10.1 Germany
- 15.10.2 U.K.
- 15.10.3 France
- 15.10.4 Italy
- 15.10.5 Spain
- 15.10.6 Russia
- 15.10.7 The Netherlands
- 15.10.8 Belgium
- 15.10.9 Turkey
- 15.10.10 Rest of Europe
- SECTION 16 - ASIA-PACIFIC ANTIVIRAL DRUGS MARKET
- 16.1 Asia-Pacific Summary
- 16.2 Market Attractive Index
- 16.3 Asia-Pacific Antiviral Drugs Market, by Type (2019-2032)
- 16.4 Asia-Pacific Antiviral Drugs Market, by Drug Class (2019-2032)
- 16.5 Asia-Pacific Antiviral Drugs Market, by Age Group (2019-2032)
- 16.6 Asia-Pacific Antiviral Drugs Market, by Distribution Channel (2019-2032)
- 16.7 Asia-Pacific Antiviral Drugs Market, by Target Indication (2019-2032)
- 16.8 Asia-Pacific Antiviral Drugs Market, by Drug Target (2019-2032)
- 16.9 Asia-Pacific Antiviral Drugs Market, by Type of Therapy (2019-2032)
- 16.10 Asia-Pacific Antiviral Drugs Market, by Country (2019-2032)
- 16.10.1 China
- 16.10.2 India
- 16.10.3 Japan
- 16.10.4 South Korea
- 16.10.5 Singapore
- 16.10.6 Malaysia
- 16.10.7 Australia
- 16.10.8 Thailand
- 16.10.9 Philippines
- 16.10.10 Rest of Asia-Pacific
- SECTION 17 - SOUTH AMERICA ANTIVIRAL DRUGS MARKET
- 17.1 South America Summary
- 17.2 Market Attractive Index
- 17.3 South America Antiviral Drugs Market, by Type (2019-2032)
- 17.4 South America Antiviral Drugs Market, by Drug Class (2019-2032)
- 17.5 South America Antiviral Drugs Market, by Age Group (2019-2032)
- 17.6 South America Antiviral Drugs Market, by Distribution Channel (2019-2032)
- 17.7 South America Antiviral Drugs Market, by Target Indication (2019-2032)
- 17.8 South America Antiviral Drugs Market, by Drug Target (2019-2032)
- 17.9 South America Antiviral Drugs Market, by Type of Therapy (2019-2032)
- 17.10 South America Antiviral Drugs Market, by Country (2019-2032)
- 17.10.1 Brazil
- 17.10.2 Argentina
- 17.10.3 Chile
- 17.10.4 Colombia
- 17.10.5 Rest of South America
- SECTION 18 - MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET
- 18.1 Middle East and Africa Summary
- 18.2 Market Attractive Index
- 18.3 Middle East and Africa Antiviral Drugs Market, by Type (2019-2032)
- 18.4 Middle East and Africa Antiviral Drugs Market, by Drug Class (2019-2032)
- 18.5 Middle East and Africa Antiviral Drugs Market, by Age Group (2019-2032)
- 18.6 Middle East and Africa Antiviral Drugs Market, by Distribution Channel (2019-2032)
- 18.7 Middle East and Africa Antiviral Drugs Market, by Target Indication (2019-2032)
- 18.8 Middle East and Africa Antiviral Drugs Market, by Drug Target (2019-2032)
- 18.9 Middle East and Africa Antiviral Drugs Market, by Type of Therapy (2019-2032)
- 18.10 Middle East and Africa Antiviral Drugs Market, by Country (2019-2032)
- 18.10.1 Kingdom of Saudi Arabia
- 18.10.2 South Africa
- 18.10.3 U.A.E.
- 18.10.4 Egypt
- 18.10.5 Rest of Middle East and Africa
- SECTION 19 - COMPANY SHARE ANALYSIS
- 19.1 Global Antiviral Drugs Market, Company Share Analysis
- 19.2 North America Antiviral Drugs Market, Company Share Analysis
- 19.3 Europe Antiviral Drugs Market, Company Share Analysis
- 19.4 Asia-Pacific Antiviral Drugs Market, Company Share Analysis
- SECTION 20 - COMPANY PROFILES
- 20.1 Gilead Sciences
- 20.1.1 Company Snapshot
- 20.1.2 Financial Overview
- 20.1.3 Product Portfolio
- 20.1.4 Recent Developments
- 20.2 AbbVie, Inc
- 20.2.1 Company Snapshot
- 20.2.2 Financial Overview
- 20.2.3 Product Portfolio
- 20.2.4 Recent Developments
- 20.3 Merck & Co
- 20.3.1 Company Snapshot
- 20.3.2 Financial Overview
- 20.3.3 Product Portfolio
- 20.3.4 Recent Developments
- 20.4 GlaxoSmithKline plc
- 20.4.1 Company Snapshot
- 20.4.2 Financial Overview
- 20.4.3 Product Portfolio
- 20.4.4 Recent Developments
- 20.5 Aurobindo Pharma Limited
- 20.5.1 Company Snapshot
- 20.5.2 Financial Overview
- 20.5.3 Product Portfolio
- 20.5.4 Recent Developments
- 20.6 Ohnson & Johnson
- 20.6.1 Company Snapshot
- 20.6.2 Financial Overview
- 20.6.3 Product Portfolio
- 20.6.4 Recent Developments
- 20.7 Sun Pharmaceutical Industries Ltd
- 20.7.1 Company Snapshot
- 20.7.2 Financial Overview
- 20.7.3 Product Portfolio
- 20.7.4 Recent Developments
- 20.8 Cipla, Inc
- 20.8.1 Company Snapshot
- 20.8.2 Financial Overview
- 20.8.3 Product Portfolio
- 20.8.4 Recent Developments
- 20.9 Mylan N V
- 20.9.1 Company Snapshot
- 20.9.2 Financial Overview
- 20.9.3 Product Portfolio
- 20.9.4 Recent Developments
- 20.10 Bristol-Myers Squibb
- 20.10.1 Company Snapshot
- 20.10.2 Financial Overview
- 20.10.3 Product Portfolio
- 20.10.4 Recent Developments
- SECTION 21 - RELATED REPORTS
- SECTION 22 - DISCLAIMER
RESEARCH METHODOLOGY
The research methodology employed in Uniprism Market Research involves four basic steps namely research and data collection, data pre-processing, modeling and forecasting, quality assurance and output.
RESEARCH AND DATA COLLECTION
A tripod model research technique is followed for research and data collection in which various approaches such as primary research, secondary research, and product mapping are considered.
Primary research basically involves the process of conducting personalized interviews with market related professionals of major market players, investors, distributors, vendors and many more.
The secondary research include data published by government, annual reports, press releases, investor presentations of companies, white papers, certified publications, annual manufacturing limit of the respective industries related to the market, production consumption analysis of certain products respective to the market and many more.
Below mention are few of the sources which we have considered while estimating the market size:
For instance,
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
Product mapping means the process of mapping the list of products that a key player contributes to the market as well as estimating the revenue of those products in order to define the Global Company share analysis of the respective Global Company in global, regional, and country level markets.
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
The process of developing mathematical, statistical, or computational representations of real-world occurrences or relationships is known as modelling. These models are intended to replicate and explain market interactions, interdependence, and dynamics. These models are used by Uniprism Market Research to acquire a better knowledge of numerous market characteristics such as customer preferences, pricing elasticity, competition dynamics, and more. Depending on the individual study aims, many types of models are utilized, such as regression models, econometric models, decision tree models, and machine learning models.
Forecasting is the process of predicting future market conditions, trends, and occurrences using past data and models. Forecasting is used by Uniprism Market Research to estimate future sales, demand for products or services, market growth, and other important performance metrics. Forecasting accurately can assist organizations in making educated decisions about resource allocation, pricing, inventory management, and marketing tactics.
We create standardized bottom-up or top-down models that scale by leveraging data science and machine learning technology. All our market models consider the unique market characteristics of each country. Forecasting is based on major market indicators and a combination of traditional methodologies, such as exponential smoothing, time series analysis, regression analysis, and more modern techniques such as machine learning algorithms are all forecasting methodologies. The method chosen is determined on the nature of the data and the specific forecasting aims.
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.